Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease
The purpose of this study is to learn about the effects of a new drug called gentenerumab. Gentenerumab is an investigational drug being studied by Roche. We are interested to know it's effect on how fast symptoms get worse in people who may be in the early stages of Alzheimer's disease. This stage of disease is also called prodromal Alzheimer's disease.
Memory loss that might progress to Alzheimer's disease
We are looking for generally healthy 50-85 year old people who have study partners who have noticed a decrease in their memory in the last 12 months but do not have a diagnosis of dementia for a study focused on prodromal Alzheimer's disease or Mild Cognitive Impairment. Admission into this study will be based on memory testing, cerbebrospinal fluid analysis and an MRI scan as well as a physical and neurological exam. People who enter this study will need a study partner who is willing to accompany them to some visits.
50 - 85
Healthy Volunteers Needed
Duration of Participation
2 1/4 years
Lisa Loree (503) 494-7615
$50.00 to $ 100.00 per visit